Pharmaceuticals, Biotechnology and Life Sciences
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up…
Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO…
Webcast set for 8:30 a.m. ET on December 3rdSALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq:…
MONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) — Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today…
TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and…
Subject to final state approval, the Dispensing Organization License grants Verano permission to cultivate, process and dispense medical cannabis across…
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending…
• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner…
Strengthening MN-001’s Scientific Foundation and Clinical OutlookLA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — Dear Fellow Shareholders, Following the…